Biotop-report 2013

Contact us: 

Phone: +49 (0)30 / 2125-4747 

E-mail: [e-mail]

www.ibb.de/wachsen

Our tailored fi nancing are your key to success. 

Our consultants look forward to meeting you.

Getting your 

innovation going.

120501_IBBanz_biotop12_210x297.indd   1

16.04.12   10:25

---

8

BioTOPics 46 | September 2013 

BioTOP-Report

 Biotechnology 

Epigenomics also found a new partner in BioChain, a leading 

clinical diagnostics provider for oncological and genetic tests. 

This company will offer Epigenomics customers the Septin9 test 

through its independent Chinese reference laboratory in Beijing 

and thereby prepare the ground for Epigenomics’ market entry 

in China.

The Institut für Produktqualität (ifp) and Romer Labs, a global-

ly leading company in the field of food diagnostics, have agreed 

on the joint launch of a new product line for enzymatic food an-

alytics. The two companies are expanding their existing cooper-

ation with this global marketing collaboration. The new Enzyme-

Fast

®

 product line transfers the traditional enzymatic methods 

to a microtiter plate kit format, thereby providing a significant 

advantage in routine food analytics.

CellTrend GmbH announced its partnership with the American 

company One Lambda Inc. The aim of this cooperation is to sup-

ply transplantation centres worldwide with innovative diagnos-

tic products developed by CellTrend. Under the agreement, One 

Lambda will receive the exclusive global distribution license for 

the immunoassay EIA for quantitative determination of anti-an-

giotensin II-receptor 1 antibodies (AT1R). AT1R is involved in a 

range of neurohumoral systems and expressed in many organs, 

including the heart, liver, lung and kidneys.

co.don AG in Teltow, one of the leading manufacturers of en-

dogenous cartilage cell transplants for the treatment of joint and 

disc damage, achieved a further milestone on the road to central 

approval. Recruitment for the clinical Phase-II trial was success-

fully completed in June 2012. In this clinical long-term study, 75 

patients with cartilage defects in the knee joint were treated with 

co.don chondrosphere

®

, an endogenous matrix-associated trans-

plant of patient cartilage cells. The extensive approval documen-

tation was filed with the European pharmaceuticals agency EMA 

in London at the end of the year.

Biochrom AG announced that Merck closed a definitive agree-

ment on the acquisition of Biochrom AG on 22 August 2012. The 

acquisition is subject to the usual preconditions for execution 

such as approval by the competent anti-trust authority. The Berlin 

location of Biochrom AG is being retained. The activities of Bio-

chrom are being integrated into the Process Solutions business 

unit of Merck Millipore. 

The Indian corporation Piramal took over the molecular imaging 

pipeline of Bayer Healthcare in April 2012. The acquired PET ra-

diopharmaceuticals have been researched and developed further 

since then in the Berlin laboratories of Piramal Imaging. The port-

folio also includes the rights to florbetaben, a highly specific sub-

stance for determination of beta-amyloid deposits in the brain, 

which is a marker for Alzheimer’s disease. A Phase-III trial of flor-

betaben was completed successfully. With the development of 

its innovative PET radiopharmaceuticals for molecular imaging, 

Piramal is focused on a key future field in modern medicine.

Alacris Theranostics GmbH closed an agreement with 

GlaxoSmithKline (GSK) which entitles GSK to use the proprietary 

ModCellTM system of Alacris for pharmaceuticals stratification 

with its own data from the early stages of cancer research at GSK. 

The system was developed at the Max Planck Institute for Molec-

ular Genetics and licensed exclusively to Alacris.

Dr. Ludger Dinkelborg

Managing Director of 

Piramal Imaging GmbH

In the Piramal Group’s cluster-based thinking, the Berlin loca-

tion unequivocally represents know-how and a long tradition 

in the field of diagnostic imaging. After all, this is where the 

first contrast medium was invented back in the 1930s. There 

is top personnel here: the training situation is excellent, both 

in companies like Bayer and in the local academic institutions. 

We collaborate closely with eminent experts from Charité hos-

pital – a key partner for clinical trials - in the field of molecular 

imaging and in the diagnosis of Alzheimer’s disease In the 

capital region are many small companies in the fields of radio-

pharmaceuticals and diagnostics, and many service provid-

ers supporting clinical research. Berlin is a global metropolis 

offering a high quality of life, the kind of place where people 

like to live and work. That makes it easy to recruit interna-

tional experts.

---

BIOCOM AG  |  Lützowstraße 33–36  |  10785 Berlin | Germany

www.biocom.de  |  Tel. [phone]  |  Fax [phone]

A AT  T G A  C AC  AC G T TC  GC C GAT  A AG GA A G T T  ATG  GA A C C T

GGA  C C A  T C A  C GA TA A  A AC GGA C A A T TA   C C C  GAT  TGG A A A

AT C  GA A AC C  GA A TC A GC C AG T C A A GA A G C T  T TC  GAC T G C

G TA  T T G  C A A GGC C AC C AG TAG  C AC AC G TGC  GGA AC G A C A

TA A  A C T  GGA AC A AGA TC C  AAA GC T  T A T  TGG  A AG TGC  C C G

C C A 

STudieS & ConSulTinG

  GC A TA C  C A A TGC  ATG  C AC GGA

AGG T TC  G TA   T TA  AC T AGA GAT  C AT   T C T  A AC C C T T A T   AGC 

G T T 

ConferenCeS

  AAG GAG ATC  C C C T TG  AC C  GGC C GG T T T

TC C C TC  C TG  GC G G TG TC A  A AT  C AG TGA  C GA C C G T G T  AC A

AC A 

BookS

TC  TC G  C C A TA A  C G T TGG C T T  A A A GC T TA G  GC C

GCC ACG 

GA A AC G GG T GAC GGG A AT  C C A AC C  GAC AGA A T T

TGA 

T V & Video

AC  TC C GC A C AT  T TG  C GA GC T AGA ACG  T A A

GC C TA G  GC T  C A A A AC GC A T G T  GC C G AT  C A A GA A T G C  A AG

G AT  

CorporATe  puBliShinG

 T T T  GGA  GA A C T A  AC A T C T  A G A

AT C  C AG C T T  AC C  AGA TGC  AAG AT C  T T G   GGA GGC A C T  GAG

G TA  

inTerneT

 C TC  C GC AC G TC C A AT  GGA  AT C   G TA  TA A  C C A

AGG G T T  TC C  AC A 

GCC 

TGA  GC C G AT  AT C   G TA   AGG TGA  C A A

GA A 

MAGAzineS

G A  T TC  G TC  C TC AG T 

ACG 

T C A  TA G  C A A A C T

C AC T C A  AC C  C A A GGA G T T  G TA  C TA  C TG  C GC GA A C T T  AC G

C GA 

eVenT MAnAGeMenT

TA  GC G TC G  AC G C AC  C A A T G C  A C C

GC C A AC GC C C AG TC C A T T  AGA GAG TC A  TA A  GAC GC A GC A

C A A C AC GC T  G T T   C C C GGA TGC A C A  GC C AGG  A C T  C T T  T G C

AGC GGC AAA  GC A C AT  C C A AGA GA A TGG  GAC AC G TGC  C AC

AC C GGC GC A T G T   T G A  C AC A AT  C AG C C T  G A T  TAG  C AC C AG

TA A  G C T  AGA C A A AC A T C T  

W e   C r e AT e   k n o W l e d G e !

 T G G

AG T G T T  C T C   A AG GA A TGA  C GA T G T  GC C T T G  AC C TC G  AC G

G T T  A C T  AC G T C C  TGC AT G  T T G  C GA T T G   GGA AGA A A A C T C

Biocom_A4_mr1.indd   1

05.10.2011   16:22:39 Uhr

---